RHON-KLINIKUM AG closed the first nine months of 2026 with strong earnings growth, reporting an 8.3% increase in patients treated and a consolidated profit of EUR 32.7 million, up from EUR 25.1 million in the prior-year period. The group treated 764,248 inpatients and outpatients across its hospitals and medical care centres, while consolidated revenue rose to EUR 1,303.8 million from EUR 1,262.1 million. EBITDA also improved to EUR 83.9 million, compared with EUR 71.8 million in the first nine months of 2025.
The results were supported by a 3.25% billing surcharge on hospital services, accounted for under "other income" through October 2026, which is intended to offset increases in personnel and non-personnel costs from previous years. The increase in consolidated profit is primarily attributed to higher capacity utilization at clinics and medical care centres, as well as growth in patient numbers, particularly in the outpatient sector. The company’s strong capital base, reflected in an equity ratio of 74.7%, provides a solid foundation for optimising inpatient and outpatient care structures.
Dr. Gunther K. WeiB, member of the Board of Management of RHON-KLINIKUM AG, stated: "Our successful third quarter shows that financial stability and medical excellence are inseparable, going hand in hand. Underlying this success is the tremendous trust our patients put in us. This sustainable basis is what allows us to continue making targeted investments in state-of-the-art medical technology and care offerings."
Those investments include the deployment of a state-of-the-art photon-counting computer tomograph at Universitätsklinikum Marburg, making RHON-KLINIKUM AG the only hospital group in Germany with four newest-generation units in operation. Additionally, a new hybrid operating theatre in Frankfurt (Oder) has expanded the hospital’s treatment range, strengthening interdisciplinary structures and enhancing care offerings in the Ostbrandenburg region. Dr. Stefan Stranz, also a member of the Board of Management, commented: "This forward-looking investment strategy ensures that we can continue to operate effectively in a market environment facing far-reaching and sweeping change. Thanks to our solid financial basis and our collaboration within the ASKLEPIOS Group network, we can take on and actively shape this transformation process from a position of strength."
For the full year 2026, RHON-KLINIKUM AG expects revenues of EUR 1.7 billion within a range of plus or minus 5%, and EBITDA between EUR 110 million and EUR 125 million. The company also anticipates a moderate improvement in the number of cases and cost weights compared with the previous year. However, the outlook is subject to significant uncertainties stemming from the Hospital Reform Adjustment Act (KHAG), which entered into force on 15 April 2026, and the Statutory Health Insurance Contribution Rate Stabilisation Act (GKV-BStabG), adopted on 10 July 2026. While these laws aim to enhance quality and efficiency, they are expected to put hospitals under greater financial pressure in the short term. Ongoing global crises and economic impacts, including higher prices, supply bottlenecks and market volatility, further complicate the forecast.
The quarterly statement for Q3 2026 is available on the Internet, and additional information about the company can be found at www.rhoen-klinikum-ag.com. RHON-KLINIKUM AG operates five highly specialised maximum- and intermediate-care facilities and employs over 19,100 people, treating approximately 938,000 patients annually.
